Skip to main content
SpringerLink
Log in

RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine

  • Protocol
  • First Online:
Multiple Myeloma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1792))

Abstract

RNA sequencing is a recently developed approach for transcriptome profiling with several advantages over gene expression profiling using DNA microarrays. Here we describe a RNA-sequencing protocol optimized for low-input analysis of total RNA from CD138+ purified plasma cells from myeloma patients which is applicable in clinical routine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31(34):4325–4332

    Article  Google Scholar 

  2. Seckinger A, Hose D (2015) Dissecting the Clonal Architecture of Multiple Myeloma. Paper presented at the 20th Congress of the European Hematology Association, Vienna, Austria

    Google Scholar 

  3. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, Vos JD, Hundemer M, Condomines M, Bertsch U, Rossi J-F, Jauch A, Klein B, Möhler T (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114(1):128–143

    Article  CAS  Google Scholar 

  4. Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, Seckinger A, Benner A, Shaughnessy JD, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Mohler T, Rossi JF, Jauch A, Klein B, Goldschmidt H (2011) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96:87–95

    Article  Google Scholar 

  5. Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, Vos JD, Rossi J-F, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18):4331–4340

    Article  CAS  Google Scholar 

  6. Seckinger A, Meißner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Reme T, Rosen-Wolff A, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D (2012) Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120(5):1087–1094. https://doi.org/10.1182/blood-2012-03-415588

    Article  CAS  PubMed  Google Scholar 

  7. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, Vos JD, Rossi JF, Möhler T, Klein B, Hose D (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28(44):3866–3879

    Article  CAS  Google Scholar 

  8. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa A-M, Sotto J-J, Wetterwald M, Dumontet C, Fuzibet J-G, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau J-L, Facon T, Mathiot C (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe francophone du Myelome. Blood 109(8):3489–3495

    Article  CAS  Google Scholar 

  9. Meißner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D (2011) Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 17(23):7240–7247

    Article  Google Scholar 

  10. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276–2284

    Article  CAS  Google Scholar 

  11. Reme T, Hose D, Theillet C, Klein B (2013) Modeling risk stratification in human cancer. Bioinformatics 29(9):1149–1157. https://doi.org/10.1093/bioinformatics/btt124

    Article  CAS  PubMed  Google Scholar 

  12. Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau J-L, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S, du Myélome IF (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe francophone du Myélome. J Clin Oncol 26(29):4798–4805

    Article  CAS  Google Scholar 

  13. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296–303

    Article  CAS  Google Scholar 

  14. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD (2006) The molecular classification of multiple myeloma. Blood 108(6):2020–2028

    Article  CAS  Google Scholar 

  15. Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD (2017) Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31(3):396–410

    Article  CAS  Google Scholar 

  16. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 3(8):862–869. https://doi.org/10.1158/2159-8290.CD-13-0014

    Article  CAS  PubMed  Google Scholar 

  17. Seckinger A, Meissner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D (2015) miRNAs in multiple myeloma—a survival relevant complex regulator of gene expression. Oncotarget 6(36):39165–39183. https://doi.org/10.18632/oncotarget.5381

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was in part supported by grants from the German Federal Ministry of Education (BMBF) within the framework of the e:Med research and funding concept “CLIOMMICS” (01ZX1309 and 01ZX1609) and the Deutsche Forschungsgemeinschaft (DFG SFB/TRR79; TP B1 and B12).

Author information

Authors and Affiliations

  1. Labor für Myelomforschung, Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany

    Anja Seckinger, Tomi Bähr-Ivacevic & Dirk Hose

  2. Genomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany

    Vladimir Benes

Authors
  1. Anja Seckinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomi Bähr-Ivacevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vladimir Benes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dirk Hose
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Hose .

Editor information

Editors and Affiliations

  1. Janssen R&D, Spring House, PA, USA

    Christoph Heuck

  2. The Myeloma Institute, University of Arkansas for Medical Science, Little Rock, AR, USA

    Niels Weinhold

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Seckinger, A., Bähr-Ivacevic, T., Benes, V., Hose, D. (2018). RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine. In: Heuck, C., Weinhold, N. (eds) Multiple Myeloma. Methods in Molecular Biology, vol 1792. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7865-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7865-6_7

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-7864-9

  • Online ISBN: 978-1-4939-7865-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation